The present invention provides compounds and pharmaceutical compositions adapted to reduce a load of an RNA virus by at least 50% the virus causing a pathogenic disease in a mammalian subject the compound adapted to inhibit the formation of S adenosyl methionine (SAM) in the virus the compound being a DOTIL inhibitor wherein the compound has a molecular weight of less than 1000 and a therapeutic index (TI= ED/LD) greater than 30 in the mammalian subject.